Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

study hypothesis to examine the acute effects on glycaemia and islet hormone secretion of increased levels of endogenous GLP-1 and GIP on islet cell function in men with type 2 diabetes. To this purpose, a standardized mixed meal test will be ingested with or without concomitant administration of sitagliptin (100mg).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lund University
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Caucasian men with type 2 diabetes diagnosed according to ICD10

• Ongoing treatment with life style adjustment or life style adjustment together with metformin as oral antidiabetic. Metformin therapy should not exceed 2 grams daily

• Age 20-75 years

• HbA1c ≤80 mmol/mol

• BMI: 20-40 kg/m2

Exclusion Criteria:

• Liver disease or ALAT three times above upper reference range

• Diabetic nephropathy (GFR < 50 mL/min/1.73 m2 or albuminuria)

• Proliferative diabetic retinopathy

• Treatment with any glucose-lowering medication except metformin

• Previous myocardial infarction, coronary heart disease or insatiable angina pectoris in the last 6 months.

• Previous surgery on the gastrointestinal tract

• Larger surgical intervention during the last 12 weeks

• Treatment with oral steroids or thiazide diuretics

• Treatment with digoxin

• Smokers

• Participation in another study the last 4 weeks

• Paracetamol intolerance